Search Results
Your search for The ASCO Post matches 17415 pages
Showing 3501 - 3550Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Current Practice
The rising incidence and prevalence of gastroenteropancreatic endocrine tumors make them the second-most prevalent gastrointestinal cancer.1 Although most of these tumors are relatively slow growing, their histologic grade and differentiation are closely correlated with their clinical behavior.2,3...
ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health Policy
The Association of Community Cancer Centers (ACCC) announced that Matt Devino, MPH, has joined the organization as Director, Cancer Care Delivery and Health Policy. Mr. Devino will lead the organization’s initiatives to improve cancer care delivery and promote health equity across rural, urban,...
ARIES Trial: Avelumab Failed to Improve 1-Year Survival in PD-L1–Positive Advanced Urothelial Cancer
First-line treatment with the PD-L1 antibody avelumab failed to meet the primary endpoint of an improvement in overall survival at 1 year for patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer. However, the objective response and disease control rates were favorable in...
B.J. Rimel, MD, Named Medical Director, Cancer Clinical Trials Office
Gynecologic oncologist and surgeon B.J. Rimel, MD, recently was named Medical Director of the Cedars-Sinai Cancer Clinical Trials Office. She will serve as a medical liaison between clinical trial principal investigators and Cedars-Sinai Cancer leadership to ensure the quality of services provided...
KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide
Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal...
The University of Texas MD Anderson Cancer Center Launches James P. Allison Institute
Today, The University of Texas MD Anderson Cancer Center launched the James P. Allison Institute, a visionary research and innovation hub within MD Anderson designed to foster groundbreaking science, to develop new treatments, and to bring the benefits of immunotherapy to all patients. The Allison...
CheckMate 9ER: Final Results Support First-Line Regimen of Nivolumab Plus Cabozantinib in Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...
Study Identifies Genetic Variants That May Contribute to Accelerated Aging in Childhood Cancer Survivors
Scientists from St. Jude Children’s Research Hospital have identified variants in two genes that may be associated with accelerated aging in childhood cancer survivors. Their research looked at the difference between the survivors’ biologic age and chronologic age. The study, published by Dong et...
FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer
On March 23, the U.S. Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor...
Tanya B. Dorff, MD, on Prostate Cancer: Early Data on PSCA-Targeted CAR T-Cell Therapy
Tanya B. Dorff, MD, of City of Hope National Medical Center, discusses the first-in-human phase I findings showing that prostate stem cell antigen (PSCA) CAR T-cell therapy is feasible in patients with metastatic castration-resistant prostate cancer, with preliminary antitumor activity exhibited.
Neil E. Fleshner, MD, MPH, on High-Risk Prostate Cancer: New Data on Abiraterone and Cabazitaxel
Neil E. Fleshner, MD, MPH, of the Princess Margaret Cancer Centre, discusses phase II results from the ACDC-RP trial, which indicate a significant tumor response to neoadjuvant abiraterone acetate plus prednisone and leuprolide, with or without cabazitaxel, in patients with high-risk prostate...
HRR Mutational Status May Be Prognostic of Survival Outcomes for Women With Recurrent Platinum-Sensitive Ovarian Cancer
Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented during the Society for Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer. The analysis, which occurred as part of a preplanned translational endpoint for the study, concluded that homologous recombination ...
Younger Patients With Appendicitis May Be at Increased Risk for Appendiceal Cancer
Although appendectomy is still the most effective treatment for acute appendicitis, nonoperative management is increasingly common, as recent studies—such as one published in November 2020 in The New England Journal of Medicine and a second published in December 2021 in the same journal—have shown...
Sequencing of Drug Combinations Could Amplify Antitumor Immune Response in Liver Cancer
A new therapeutic strategy for hepatocellular carcinoma (HCC) that initially primes the tumor with an immune checkpoint inhibitor before using a multikinase inhibitor has shown efficacy in a study published in the Journal of the National Cancer Institute. Kikuchi et al reported that the new...
Sue S. Yom, MD, PhD, on Thyroid Cancer: Expert Perspective on the State of the Field
Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses some of the latest developments in thyroid cancer, including the mutational landscape, therapies for high-risk and anaplastic diseases, and multimodalities for aggressive differentiated thyroid cancers.
Atezolizumab Plus Chemoradiation Is Safe, Demonstrates Signs of Immune Activation in Patients With Cervical Cancer
A phase I/Ib trial conducted by the National Cancer Institute’s National Clinical Trials Network group NRG Oncology, NRG-GY017, concluded that the addition of the immunotherapy atezolizumab prior to and concurrently given with chemoradiation was safe for women with node-positive, locally advanced...
SORAYA Trial: Antibody-Drug Conjugate Produces Remissions in One-Third of Patients With Drug-Resistant Ovarian Cancer
In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel antibody-drug conjugate therapy produced a substantially better response than standard treatments, investigators from Dana-Farber Cancer Institute reported at the Society of...
Abemaciclib/Letrozole in Patients With Recurrent ER-Positive Endometrial Cancer
A combination therapy caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor (ER)-positive endometrial cancer, results from a recent clinical trial show. Trial leaders from Dana-Farber Cancer Institute presented the findings at the Society of...
FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma
On March 21, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient (as determined by an FDA-approved test). Eligible patients have disease...
Elizabeth D. Cash, PhD, on Addressing the Psychological Aspects of Head and Neck Cancer
Elizabeth D. Cash, PhD, of the University of Louisville, discusses depression among patients with head and neck cancer, the impact it can have on prognosis, and the importance of helping patients cope through screening for depressive symptoms and treatment with collaborative care models.
Michelle Mierzwa, MD, on Oropharyngeal Cancer: Early Results on De-escalated Radiotherapy
Michelle Mierzwa, MD, of the University of Michigan, discusses early findings from a phase II trial of FDG-PET (fluorodeoxyglucose–positron-emission tomography) de-escalated radiotherapy for patients with p16-positive orophyaryngeal cancer. An interim analysis suggests that for approximately half...
FDA Approves Nivolumab/Relatlimab-rmbw for Unresectable or Metastatic Melanoma
On March 18, the U.S. Food and Drug Administration (FDA) approved nivolumab and relatlimab-rmbw (Opdualag) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. The approved treatment is a fixed-dose combination of the LAG-3–blocking antibody relatlimab ...
ASCO and ECO Present Update on How the War in Ukraine Is Impacting Care for Patients With Cancer
Today, ASCO and the European Cancer Organisation (ECO) held a virtual briefing with oncologists in Ukraine, Poland, and Romania to address the impact the war is having on patients with cancer displaced within Ukraine and those fleeing to neighboring countries. The briefing also included remarks...
Half of Patients With Cancer and Survivors Report Incurring Cancer-Related Medical Debt
The cost of cancer care is substantially impacting the lives of patients with cancer and survivors, forcing them to make significant lifestyle changes and causing some to incur long-term medical debt. According to a new Survivor Views survey from the American Cancer Society Cancer Action Network...
Genitourinary Oncology 2021–2022 Almanac
The past year has witnessed tremendous advances in genitourinary oncology. I am pleased to review these findings in this year’s Genitourinary Oncology Almanac from The ASCO Post. I hope that you will find this roadmap helpful in highlighting a selection of these exciting developments. Checkpoint...
Expert Point of View: Celestia S. Higano, MD
MAGNITUDE is challenging from a statistical point of view,” said formal discussant Celestia S. Higano, MD, currently Adjunct Professor, Department of Urologic Sciences at the University of British Columbia, Vancouver, Canada, and formerly of Fred Hutchinson Cancer Research Center in Seattle....
PARP Inhibitor Plus Abiraterone Benefits Subgroups of Patients With Metastatic Castration-Resistant Prostate Cancer
The combination of the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib plus abiraterone acetate and prednisone as first-line therapy significantly improved radiographic progression-free survival vs abiraterone and placebo alone in men with metastatic castration-resistant prostate cancer...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
Oncolytic Virus Plus Nivolumab Demonstrates Durable Response in Nonmelanoma Skin Cancer of the Head and Neck
Intratumor injection of the oncolytic virus RP1 in combination with the checkpoint inhibitor nivolumab has demonstrated durable antitumor activity in patients with nonmelanoma skin cancer of the head and neck, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers...
David S. Hong, MD, on New Findings on Tisotumab Vedotin-tftv in Patients With Head and Neck Squamous Cell Carcinoma
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase II cohort, which suggest favorable antitumor activity with tisotumab vedotin-tftv in patients with head and neck squamous cell carcinoma that has progressed after treatment with a...
Peter Zeng, MD/PhD Candidate: Immune Cell Signature Predicts Survival in HPV-Associated Head and Neck Cancer
Peter Zeng, MD/PhD Candidate, at Ontario’s Western University, discusses a three-gene prognostic classifier tool, known as UWO3, which was validated in six external cohorts and shown to identify patients with human papillomavirus–related head and neck cancer that is likely to recur following...
ASCO and the European Cancer Organisation to Hold Briefing on Providing Cancer Care During the War in Ukraine
ASCO and the European Cancer Organisation (ECO) will hold a joint session on Friday, March 18, from 9:00–10:00 AM ET, 14:00–15:00 CET, to discuss the current situation of refugees fleeing Ukraine and the impact the war is having on the ability of oncologists in Ukraine, Poland, and Romania to care...
Study Finds Cancer Treatment May Create Employment Difficulties for Some Rural Women
Rural women are likely to face significant challenges finding secure and reliable employment following cancer treatment if they did not already have a secure job at the time of their diagnosis, according to a new study led by University of Arkansas for Medical Sciences (UAMS) researchers. The...
Nancy Lee, MD: Toward Personalization of Radiotherapy for HPV-Related Oropharyngeal Carcinoma
Nancy Lee, MD, of Memorial Sloan Kettering Cancer Center, discusses results from the 30ROC trial, which showed that intratreatment FMISO [(18)F-fluoromisonidazole] PET response could identify patients with human papillomavirus–positive oropharyngeal carcinoma who may be sensitive to radiation...
Glenn J. Hanna, MD, on Oropharyngeal Squamous Cell Carcinoma: Detecting Occult Recurrence
Glenn J. Hanna, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings that show human papillomavirus circulating tumor DNA (HPV ctDNA) may be useful as part of surveillance monitoring of patients with oropharyngeal squamous cell carcinoma. Dr. Hanna reports that 93% of...
Pfizer Announces Plan to Maintain Humanitarian Supply of Medicines to Russians, Donate All Proceeds to Humanitarian Support for the People of Ukraine
On March 14, Pfizer issued the following statement on its company position in Russia. Pfizer stands with the unified global community across the public, private, and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created. The international...
New Research Measures Decrease in Cancer Detection Due to the COVID-19 Pandemic
Research published in JNCCN—Journal of the National Comprehensive Cancer Network examined data from the Ontario Cancer Registry from September 25, 2016, through September 26, 2020, to determine the impact of the COVID-19 pandemic on the number of new cancer cases detected. The researchers found...
Sumanta K. Pal, MD, on Advances in Genitourinary Cancer Treatment: Expert Perspective
Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses some key research developments in kidney cancer, including data on nivolumab and ipilimumab with or without CBM588 in metastatic renal cell carcinoma; intestinal microbiome associated with the development of grade 3 or 4 adverse ...
War Is Hell. It’s Also a Public Health Disaster, Especially for People With Cancer
We are all following the ongoing Russian invasion of Ukraine with surprise and horror. I’m sure few readers of The ASCO Post imagined the invasion of a European country by its European neighbor was possible again, naively thinking wars like this ended with the Allied victory in World War II. But...
Novel Radioligand Therapy Improves Progression-Free and Overall Survival in Patients With Metastatic Prostate Cancer
A novel prostate cancer treatment—actinium Ac-225–PSMA-617 radioligand therapy—has been shown to increase the progression-free and overall survival of patients with metastatic castration-resistant prostate cancer, according to research published by Sathekge et al in the Journal of Nuclear Medicine. ...
FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
On March 11, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant...
KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
Study Patients With Dual Medicare and Medicaid Eligibility Have Poorer Outcomes, Higher Spending After Oncologic Surgery
They’re old enough to qualify for Medicare, and their incomes are low enough to qualify them for Medicaid. However, recent research has found that when these “dual eligible” patients have surgery to remove a cancerous tumor, they suffer more complications, stay in the hospital longer, and have a...
Study Shows Structural Racism May Contribute to Poorer Outcomes in Black and Hispanic Patients With Leukemia
Black and Hispanic people with acute myeloid leukemia (AML) in the greater Chicago area were more likely to die from the disease than their non-Hispanic White counterparts, with a 59% and 25% greater risk, respectively, according to a new study led by University of Illinois Chicago researchers. In...
The Virtues of Ruth: Gratitude, Advocacy, and Service
I still remember having to sit down with her three siblings on that afternoon. It was drizzling, cloudy, and cool—Mother Nature in agreement with the heaviness of what had just taken place. I held them tight. I knew the words I would utter next would change their lives forever. I paused for 10...
Managing Long-Term Toxicity From Pelvic Radiation Therapy
Advances over the past 3 decades in improvements in cancer prevention and screening strategies and more effective diagnostics and therapies in cancer care have led to unprecedented declines in death rates from all cancers, including prostate, gynecologic, and colorectal/anal cancers. The fastest...
Project Confirm: An Initiative to Promote Transparency of the Accelerated Approval Program for Oncology Indications
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Gautam U. Mehta, MD, Neurosurgical Oncologist and Clinical Reviewer, Division of Oncology 2; Fatima Rizvi,...
